MD4591B1 - Dispersie solidă a unui modulator selectiv al receptorului de progesteron - Google Patents

Dispersie solidă a unui modulator selectiv al receptorului de progesteron Download PDF

Info

Publication number
MD4591B1
MD4591B1 MDA20150060A MD20150060A MD4591B1 MD 4591 B1 MD4591 B1 MD 4591B1 MD A20150060 A MDA20150060 A MD A20150060A MD 20150060 A MD20150060 A MD 20150060A MD 4591 B1 MD4591 B1 MD 4591B1
Authority
MD
Moldova
Prior art keywords
solid dispersion
progesterone receptor
selective modulator
relates
selective
Prior art date
Application number
MDA20150060A
Other languages
English (en)
Russian (ru)
Other versions
MD20150060A2 (ro
MD4591C1 (ro
Inventor
Флориан Баттюн
Пьер-Ив Жувен
Жером Эк
Оде Колен
Original Assignee
Laboratoire Hra-Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47878221&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD4591(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratoire Hra-Pharma filed Critical Laboratoire Hra-Pharma
Publication of MD20150060A2 publication Critical patent/MD20150060A2/ro
Publication of MD4591B1 publication Critical patent/MD4591B1/ro
Publication of MD4591C1 publication Critical patent/MD4591C1/ro

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Colloid Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Invenţia se referă la o dispersie solidă, care cuprinde un ingredient activ, selectat din grupa constând din modulatori selectivi ai receptorului de progesteron, metaboliţi ai acestora, amestecuri de aceşti metaboliţi, şi un excipient polimeric farmaceutic acceptabil. De asemenea, invenţia se referă la o compoziţie farmaceutică care cuprinde dispersia solidă menţionată şi la utilizările terapeutice ale acesteia.
MDA20150060A 2012-12-06 2013-12-05 Dispersie solidă a unui modulator selectiv al receptorului de progesteron MD4591C1 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1261721A FR2999081B1 (fr) 2012-12-06 2012-12-06 Dispersion solide d'un modulateur selectif du recepteur a la progesterone
PCT/FR2013/052952 WO2014087106A1 (fr) 2012-12-06 2013-12-05 Dispersion solide d'un modulateur selectif du recepteur a la progesterone

Publications (3)

Publication Number Publication Date
MD20150060A2 MD20150060A2 (ro) 2015-10-31
MD4591B1 true MD4591B1 (ro) 2018-09-30
MD4591C1 MD4591C1 (ro) 2019-04-30

Family

ID=47878221

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20150060A MD4591C1 (ro) 2012-12-06 2013-12-05 Dispersie solidă a unui modulator selectiv al receptorului de progesteron

Country Status (19)

Country Link
US (1) US20160213684A1 (ro)
EP (1) EP2928499B1 (ro)
JP (1) JP2016506390A (ro)
CN (1) CN105120899B (ro)
BR (1) BR112015013110B1 (ro)
CL (1) CL2015001559A1 (ro)
CR (1) CR20150299A (ro)
DO (1) DOP2015000137A (ro)
EA (1) EA029701B1 (ro)
EC (1) ECSP15022501A (ro)
ES (1) ES2666618T3 (ro)
FR (1) FR2999081B1 (ro)
GE (1) GEP201706740B (ro)
MD (1) MD4591C1 (ro)
MX (1) MX362151B (ro)
NI (1) NI201500076A (ro)
PE (1) PE20151783A1 (ro)
UA (1) UA115796C2 (ro)
WO (1) WO2014087106A1 (ro)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2987867C (en) 2015-06-09 2023-06-27 Capsugel Belgium Nv Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
FR3060389B1 (fr) 2016-12-20 2019-05-31 Laboratoire Hra-Pharma Comprime enrobe comprenant de l'ulipristal acetate ou un de ses metabolites
EP3492070A1 (en) * 2017-11-30 2019-06-05 BIT Pharma GmbH Process and device for preparing a solid dispersion
CN108186586B (zh) * 2018-03-01 2020-12-29 常州市第四制药厂有限公司 一种烯丙雌醇片剂及其制备方法
EP3895691A1 (en) * 2020-04-15 2021-10-20 LTS Lohmann Therapie-Systeme AG Ulipristal acetate otf
CN111714444B (zh) * 2020-06-23 2022-12-20 南京海纳医药科技股份有限公司 一种醋酸乌利司他口服固体制剂及其制备方法
CN113406230A (zh) * 2021-06-17 2021-09-17 河南泰丰生物科技有限公司 一种醋酸乌利司他固体制剂溶出曲线的测定方法
US11878025B2 (en) 2021-09-06 2024-01-23 Slayback Pharma Llc Pharmaceutical compositions of mifepristone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
JPH10505574A (ja) * 1994-07-26 1998-06-02 ラボラトワール エフィク 乾燥製剤の製造方法と、この方法で得られる医薬組成物
CA2264718C (en) * 1996-09-01 2006-05-30 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
AR033711A1 (es) * 2001-05-09 2004-01-07 Novartis Ag Composiciones farmaceuticas
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
WO2006010097A2 (en) 2004-07-09 2006-01-26 The Population Council, Inc. Sustained release compositions containing progesterone receptor modulators
EP2094275A2 (en) * 2006-12-28 2009-09-02 Repros Therapeutics Inc. Methods and formulations for improved bioavailability of antiprogestins
US8512745B2 (en) * 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
RU2542779C2 (ru) 2009-04-14 2015-02-27 Лаборатуар Хра-Фарма Способ контрацепции, используемый по мере необходимости
CN102107007B (zh) * 2011-01-28 2012-11-07 广州朗圣药业有限公司 甾体类抗孕激素组合物及其制备方法
CN102600001A (zh) * 2011-01-19 2012-07-25 国家人口计生委科学技术研究所 缓释米非司酮阴道环制剂及其应用

Also Published As

Publication number Publication date
BR112015013110A2 (pt) 2017-07-11
PE20151783A1 (es) 2015-12-20
MD20150060A2 (ro) 2015-10-31
CL2015001559A1 (es) 2016-01-04
NI201500076A (es) 2015-11-13
EA201500609A1 (ru) 2015-09-30
MD4591C1 (ro) 2019-04-30
MX362151B (es) 2018-12-24
EA029701B1 (ru) 2018-05-31
FR2999081B1 (fr) 2015-02-27
WO2014087106A1 (fr) 2014-06-12
BR112015013110B1 (pt) 2020-07-14
GEP201706740B (en) 2017-09-25
EP2928499B1 (fr) 2018-01-31
CN105120899B (zh) 2018-07-24
JP2016506390A (ja) 2016-03-03
US20160213684A1 (en) 2016-07-28
EP2928499A1 (fr) 2015-10-14
MX2015007127A (es) 2016-04-11
UA115796C2 (uk) 2017-12-26
DOP2015000137A (es) 2015-08-31
ES2666618T3 (es) 2018-05-07
CR20150299A (es) 2015-08-14
FR2999081A1 (fr) 2014-06-13
ECSP15022501A (es) 2016-01-29
CN105120899A (zh) 2015-12-02

Similar Documents

Publication Publication Date Title
MD4591B1 (ro) Dispersie solidă a unui modulator selectiv al receptorului de progesteron
PH12015501595A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501598A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MY188450A (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501600A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015501596B1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
WO2011159769A3 (en) Indane estrogen receptor modulators and uses thereof
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
IN2015DN03984A (ro)
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX359288B (es) Forma iv del clorhidrato de ivabradina.
MD20150053A2 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
MD20150054A2 (ro) Produs de comicronizare cu conţinut de un modulator selectiv al receptorului de progesteron

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees